Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.59 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.58 |
| ▸ | EDNRA | P25101 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | ECE1 | P42892 | 9/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | APAF1 | O14727 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | CTSC | P53634 | 1/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | MMP8 | P22894 | 1/20 | 0.53 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30051632 | 0.95 | CTSC (0.60) | ACEMAGI3EDNRAL3MBTL1KMT2A | |
| SCHEMBL30052954 | 0.95 | MAGI3 (0.61) | ACEMAGI3EDNRAL3MBTL1ECE1 | |
| SCHEMBL11804393 | 0.93 | ACE (0.60) | ACEMAGI3EDNRAL3MBTL1KMT2A | |
| SCHEMBL30051826 | 0.93 | ACE (0.68) | ACEECE1ERAP2 | |
| SCHEMBL7404621 | 0.92 | ACE (0.64) | ACEEDNRAL3MBTL1KMT2AECE1 | |
| SCHEMBL7404624 | 0.92 | ACE (0.64) | ACEEDNRAL3MBTL1KMT2AECE1 | |
| SCHEMBL30051740 | 0.92 | ACE (0.59) | ACEMAGI3EDNRAL3MBTL1KMT2A | |
| SCHEMBL30052328 | 0.91 | ACE (0.60) | ACEL3MBTL1ECE1KDM4EAPAF1 | |
| SCHEMBL3512696 | 0.91 | ACE (0.71) | ACEECE1 | |
| SCHEMBL5481232 | 0.91 | ACE (0.71) | ACEECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230137562-A1 | TAU AGGREGATION INHIBITORS | ADRX, INC. | 2023-05-04 | — | — | US | claimed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | ACE 1190/4885MAGI3 1924/4885EDNRA 2101/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | ACE 486/4885MAGI3 2966/4885EDNRA 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.